A recent trial revealed promising results using traditional Qiliqiangxin, in the treatment of heart failure
A recent placebo-controlled trial presented at the European Society of Cardiology (ESC) 2023 Congress has revealed promising results regarding the use of a traditional Chinese herbal remedy, Qiliqiangxin, in the treatment of heart failure with reduced ejection fraction (HFrEF). HFrEF is a condition where the heart's left ventricle loses its ability to contract effectively, leading to insufficient blood circulation. The study, known as QUEST, involved over 3,000 HFrEF patients who were randomly assigned to take Qiliqiangxin or a placebo in addition to their standard triple-therapy regimen for heart failure. Qiliqiangxin, composed of 11 plant-based ingredients known for their diuretic and cardiotonic effects, demonstrated a significant reduction in the risk of cardiovascular death and hospitalization due to heart failure by more than 20%. This reduction was consistent across various patient groups. While these findings are promising, some questions remain, including the limited enrol